Farkas Henriette, Pintér Judit, Kalabay László, Jakab László, Visy Beáta, Fekete Béla
Semmelweis Egyetem, Budapest, Altalános Orvostudományi Kar, Kútvölgyi Klinikai Tömb, Fül-orr-gégészeti-, Allergológiai- és Angiooedema Szakrendeles.
Orv Hetil. 2002 Aug 18;143(33):1929-33.
The authors appraised the clinical efficacy of mometasone furoate in patients with seasonal allergic rhinitis and rhinoconjunctivitis.
An open, two-week trial was conducted in 89 patients between 1 July and 15 September 2001. A baseline oto-rhinolaryngological examination was performed. Nasal obstruction, rhinorrhea, sneezing, and itching as well as ocular, throat and ear clinical signs and general symptoms including cough and dyspnea were characterized using a symptom score. Mometasone furoate was administered intranasally in 100 micrograms doses into both nostrils. Depending on the severity of symptoms, antiallergic eye drops and systemic antihistamines were also allowed. After two weeks of treatment, a follow-up physical examination was performed and the symptom score was re-evaluated. Potential adverse events that had occurred during the treatment period were recorded.
Mometasone furoate nasal spray alleviated all four nasal symptoms promptly and effectively. In particular, treatment resulted in a 93 percent decrease of overall symptom score. None of the participants discontinued treatment due to the occurrence of adverse effects.
These results demonstrate that mometasone furoate nasal spray is a safe and effective intranasal corticosteroid for the therapy of SAR/SARC seasonal allergic rhinitis and rhinoconjunctivitis.
作者评估了糠酸莫米松对季节性变应性鼻炎和鼻结膜炎患者的临床疗效。
于2001年7月1日至9月15日对89例患者进行了一项为期两周的开放性试验。进行了基线耳鼻咽喉科检查。使用症状评分对鼻塞、流涕、打喷嚏、瘙痒以及眼部、咽喉和耳部的临床体征和包括咳嗽及呼吸困难在内的全身症状进行了描述。糠酸莫米松以100微克的剂量经鼻分别滴入双侧鼻孔。根据症状的严重程度，也可使用抗过敏眼药水和全身性抗组胺药。治疗两周后，进行了随访体格检查并重新评估了症状评分。记录了治疗期间发生的潜在不良事件。
糠酸莫米松鼻喷雾剂迅速且有效地缓解了所有四种鼻部症状。特别是，治疗使总体症状评分降低了93%。没有参与者因出现不良反应而停止治疗。
这些结果表明，糠酸莫米松鼻喷雾剂是一种用于治疗季节性变应性鼻炎和鼻结膜炎的安全有效的鼻用皮质类固醇。
